NYSE
18.86USD
+0.28 (+1.48%)
We have scored 35 news catalysts on Takeda Pharmaceutical Company Limited (TAK) over the past 12 months. The biggest single-day move next to one of them came May 11, 2026, when TAK closed −0.6%: “HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE”. Coverage across the window leans positive (average ticker sentiment +0.34). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
60B
P/E
—
EPS
—
Beta
0.09
52W range
12.99-19.1
Day range
18.77–18.93
Open
18.84
Prev close
18.59
Volume
2.6M
Avg volume
3M
Dividend
0.63
IPO
2010-01-05
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Takeda Pharmaceutical Company Limited — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Takeda Pharmaceutical Company Limited, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for TAK: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.
